Loganin

Loganin is a type of iridoid glycoside compound that possesses anti-inflammatory, antioxidant, and antitumor properties, and offers protective effects against acute lung injury and pulmonary fibrosis. Loganin exerts its protective effects against LPS (HY-D1056)-mediated inflammation and oxidative stress by upregulating the Nrf2/HO-1 signaling pathway, and it reduces neuroinflammation caused by spinal cord injury (SCI)^{[1][2][3][4][5][6]}. In Vitro:Loganin (0-50 µM; 24 h) shows significant cytotoxicity to RAW264.7 at high concentrations^[3].
Loganin (0-30 µM; 1 h) significantly reduces the production of NO, PGE2, TNF-α, and IL-1β in RAW264.7 macrophages stimulated by LPS (100 ng/ml, 24 h) in a dose-dependent manner, and increases the expression of Nrf2 and HO-1 in a concentration-dependent manner^[3].
Loganin (30 µM; 1 h) alleviates LPS-mediated ROS generation in RAW264.7 macrophages^[3].
Loganin (0-150 μg/mL; 48 h) reduces the survival rate, migration and invasion ability of Huh7 cells^[6].
In Vivo:Loganin (1-10 mg/kg; i.p.; once daily from day 1 to day 28 after SCI) dose-dependently reduced the degree of neurological damage in rats with SCI model^[4].
Loganin (80-200 mg/kg; i.g.; 8 weeks of Bleomycin induction, twice a week from week 4 (day 28)) concentration-dependently reduced BLM-induced lung injury in mice^[5].